Characteristics of patients initiating teriparatide for the treatment of osteoporosis

被引:14
|
作者
Foster, S. A. [1 ]
Foley, K. A. [2 ]
Meadows, E. S. [1 ]
Johnston, J. A. [1 ]
Wang, S. [2 ]
Pohl, G. M. [1 ]
Long, S. R. [2 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Thomson Medstat, Ann Arbor, MI USA
关键词
bisphosphonates; demographics; osteoporosis; teriparatide; treatment;
D O I
10.1007/s00198-007-0455-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The demographic and clinical characteristics of patients initiating teriparatide were compared with those of patients initiating bisphosphonates for the treatment of osteoporosis. In these samples of commercially insured, Medicare, and Medicaid patients, patients initiating teriparatide were older, in poorer health, and appeared to have more severe osteoporosis than patients initiating bisphosphonates. Introduction The demographic and clinical characteristics of patients initiating teriparatide are compared with those of patients initiating bisphosphonates. Methods Beneficiaries (45 years and older) with at least one claim for teriparatide or a bisphosphonate from 2003 to 2005 and continuous enrollment in the previous 12 months and subsequent 6 months were identified from commercial, Medicare, and Medicaid administrative claims databases. Patients initiating teriparatide (commercial/Medicare (N=2,218); Medicaid (N=824)) were compared to patients initiating bisphosphonates (commercial/Medicare (N=97,570); Medicaid (N=77,526)) in terms of age, provider specialty, comorbidities, prior use of osteoporosis medications, fractures, BMD screening, health status, and resource utilization. Results Teriparatide patients were older and in poorer health than bisphosphonate patients. Approximately 38% of teriparatide patients in both groups had fractured in the pre-period compared to 16% of commercial/Medicare and 15% of Medicaid bisphosphonate patients. Teriparatide patients were more likely to have used osteoporosis medications in the pre-period (79.9% versus 32.1% (commercial/Medicare); 82.2% versus 19.6% (Medicaid)). Conclusions In these samples of patients, those initiating teriparatide differed from those initiating bisphosphonates. Teriparatide patients were older, in poorer health, and appeared to have more severe osteoporosis than bisphosphonate patients. Comparisons of treatment outcomes should take these differences in patient characteristics into consideration.
引用
收藏
页码:373 / 377
页数:5
相关论文
共 50 条
  • [31] Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
    Minisola, Salvatore
    Cipriani, Cristiana
    Della Grotta, Giada
    Colangelo, Luciano
    Occhiuto, Marco
    Biondi, Piergianni
    Sonato, Chiara
    Vigna, Evelina
    Cilli, Mirella
    Pepe, Jessica
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2019, 11
  • [32] Teriparatide in the treatment of glucocorticoid-induced osteoporosis
    Bilezikian, J. P.
    [J]. BONE, 2009, 45 : S131 - S131
  • [33] Analysis of daily teriparatide treatment for osteoporosis in men
    R. Niimi
    T. Kono
    A. Nishihara
    M. Hasegawa
    A. Matsumine
    T. Kono
    A. Sudo
    [J]. Osteoporosis International, 2015, 26 : 1303 - 1309
  • [34] Teriparatide treatment of osteoporosis in a patient with anorexia nervosa
    Amal Shibli-Rahhal
    Laurie McCormick
    [J]. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2013, 18 : 229 - 231
  • [35] Transient osteoporosis of the hip: successful treatment with teriparatide
    Fabbriciani, Gianluigi
    Pirro, Matteo
    Manfredelli, Maria Rosaria
    Bianchi, Massimo
    Sivolella, Silvio
    Scarponi, Anna Maria
    Mannarino, Elmo
    [J]. RHEUMATOLOGY INTERNATIONAL, 2012, 32 (05) : 1367 - 1370
  • [36] NEW RESULTS OF TERIPARATIDE IN THE TREATMENT OF SEVERE OSTEOPOROSIS
    Diez-Perez, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S781 - S782
  • [37] Teriparatide treatment of osteoporosis in a patient with anorexia nervosa
    Shibli-Rahhal, Amal
    McCormick, Laurie
    [J]. EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2013, 18 (02) : 229 - 231
  • [38] Treatment of severe osteoporosis with teriparatide: the European experience
    Adami, S.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S185 - S185
  • [39] Complicated Osteoporosis in Progeroid Syndrome: Treatment With Teriparatide
    Iglesias Bolanos, Paloma
    Guijarro de Armas, Guadalupe
    Civantos Modino, Soraya
    Vega Pinero, Belen
    Pavon de Paz, Isabel
    Monereo Megias, Susana
    [J]. JOURNAL OF CLINICAL DENSITOMETRY, 2012, 15 (01) : 116 - 119
  • [40] Evaluation of Teriparatide for Treatment of Osteoporosis in Four Patients with Cystic Fibrosis: A Case Series
    Siwamogsatham, Oranan
    Stephens, Kelly
    Tangpricha, Vin
    [J]. CASE REPORTS IN ENDOCRINOLOGY, 2014, 2014